Early Returns on the FLAURA Trial: Should Osimertinib be a First Line Agent in EGFR Mutation-Positive NSCLC? (BMIC-002)
Aug 29, 2017•5 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in patients with EGFR mutation-positive advanced NSCLC.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast